Supply Chain Resilience Measures Included In Senate Coronavirus Bill
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.
You may also be interested in...
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.
Provisions adapted from DISARM Act would carve out antimicrobials from hospital bundled payments and allow reimbursement equal to 100% of a drug’s average sales price.
Legislation allows sponsors to request HCPCS code even before US FDA approval, but would extend the sequester until 2030 to pay for the temporary increase in payments for Part B drugs.